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Abstract
Objective: Premarital hemoglobinopathy screening is one of the important procedures of hemoglobinopathy control pro-
grams. This is the first report about the prevalence of hemoglobinopathies in Kocaeli. 
Materials and Methods: The study covered screening from July 2005 to the end of December 2008. Under the auspices of 
the Ministry of Health and regional health authorities, blood samples of the couples were obtained during admission to the mar-
riage office. Complete blood counts and hemoglobin variant analysis were performed with automatic counter and high pressure 
liquid chromatography technique. Genetic counseling was given to carriers of thalassemia and abnormal hemoglobins.  
Results: A total of 88,888 people were screened. The frequencies of β-thalassemia trait and sickle cell anemia trait were 
0.89% and 0.05%, respectively. The frequency of couples with high-risk of having a sibling with homozygous hemoglobin-
opathy was 0.01%.   
Conclusion: The prevalence of β-thalassemia trait and sickle cell anemia trait was quite low and reflects the frequency in 
eastern and northern Anatolia and migration to Kocaeli from these geographic regions. Although frequency is low, the 
chronic transfusion requirement, high cost of chelating, organ damage, painful crisis and other crisis, and availability of 
stem cell transplantation only for a limited number of patients with compatible sibling donors justify premarital screening 
studies even in regions with lower prevalence such as Kocaeli. (Turk J Hematol 2009; 26: 62-6)
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Özet
Amaç:Evlilik öncesi hemoglobinopati taraması hemoglobinopati kontrol programının önemli bir parçasıdır. Bu çalışma 
Kocaeli’deki hemoglobinopati sıklığına ilişkin ilk rapordur.
Yöntemler: Çalışma Haziran 2005-Aralık 2008 dönemini kapsamaktadır. Sağlık Bakanlığının ve İl Sağlık Müdürlüğünün 
hemoglobinopati kontrol programı kapsamında evlenecek çiftlerin kanları nikah işlemleri için başvuruları sırasında alınmıştır. 
Tam kan sayımları ve hemoglobin varyant analizleri otomatik sayıcı ve yüksek basınçlı s ıvı kromotografisi tekniği ile 
çalışılmıştır. Talasemi ve anormal hemoglobin taşıyıcılarına genetik danışma verilmiştir.In  tro  duc  ti  on
Thalassemias are the most common single-gene disorders 
in the world and are real health problem, especially in the 
Mediterranean basin and in parts of Asia and the Middle East.
The expected number of carriers is 1,400,000 and the 
number of patients is approximately 5,000. In 2006, the 
Ministry of Health and Turkish National Hemoglobinopathy 
Council reported the results of screening studies (377,339 
healthy subjects) from 16 different cities and recorded the aver-
age frequency of β-thalassemia trait as 4.3%. The highest 
prevalence of β-thalassemia trait (13.1%) was in Antalya and 
Çukurova regions (10%) [1]. 
Kocaeli is a crowded city of Turkey on the north coast of 
Marmara sea with a population of approximately 1,438,000 and 
28,400 births in 2008. As an important center of industry and 
trade, its population is progressively increasing mainly due to 
migration. Turkey’s population is a mosaic of various ethnicities. 
This feature is reflected in the distribution of hemoglobinopa-
thies, thalassemia carriage being the most prevalent, followed 
by sickle cell hemoglobinopathy and others. Although 700 
structural hemoglobin variants have been identified, only three 
(HbS, HbC and HbE) reach high frequencies in the world [2].
Thalassemia major and sickle cell anemia are real burdens 
to the individual and family and health budgets. Prevention of 
births of affected children must be the main national strategy. 
The Ministry of Health and the Turkish National Hemoglobinopathy 
Council initiated a national hemoglobinopathy control program 
in 33 provinces, including Kocaeli [1].
The Kocaeli Hemoglobinopathy Screening Center (HSC) 
started premarital screening in July 2005. In the present report, 
the results of a 3.5-year premarital screening program are pre-
sented as the first report from Kocaeli covering an extensive 
number of people. 
Material and Methods
The premarital hemoglobinopathy screening program is 
operated under the auspices of the Ministry of Health and 
regional health authorities in Kocaeli. This study covered the 
results of screening from July 2005 to the end of December 
2008. Ethical approval of Kocaeli Health Directorate was 
obtained for reporting the results. During admission to the mar-
riage office, all couples were referred to local primary health 
care centers to give venous blood samples to screen for some 
contagious diseases and hemoglobinopathies. These tests 
were mandatory. The Provincial Directorate of Health con-
ducted the logistic organization, and blood samples collected 
in primary health care centers of all districts (İzmit, Derince, 
Gebze, Körfez, Gölcük, Kandıra, Karamürsel) were delivered to 
Kocaeli HSC weekly in cold chain.
In the HSC, complete blood counts and hemoglobin variant 
analysis of both partners were performed with automatic coun-
ter and high pressure liquid chromatography technique. 
Instruments used were: Mindray Medical Instruments Ltd. 
BC 5500 blood counter; Agilent Technologies Inc. 1200 series 
hemoglobin variant analyzer, distributor Betamed Tibbi Malzeme 
Ltd. (used in 2005-2007); Primus Corporation, Ultra 2 hemo-
globin variant analyzer, distributor Biocan Tıp Laboratuvar ve 
Tıbbi Malzemeler Ltd. (2008). The equipment performed hemo-
globin variant analysis by cation exchange chromatography in 
conjunction with gradient elution from hemolyzed EDTA whole 
blood. The separated hemoglobin fractions were monitored by 
means of absorption, and the chromatogram obtained was 
recorded and stored by the internal computer. To avoid techni-
cal errors, quality control was performed daily with commer-
cially available control samples.
The subjects were considered to have the β-thalassemia 
trait if they had a mean corpuscular volume (MCV) <80 fL and/
or a mean corpuscular hemoglobin (MCH) level of <27 pg and 
a hemoglobin (Hb)A2 level of >3.5% or a HbF level of >2%. HbF, 
S, C, D, E and other variants were also detected. HbA2 level 
between 3.1 and 3.5 was considered borderline. After evalua-
tion of chromatograms by the physicians of the Center (J. 
Bayram and V. Şenkal), carrier couples were invited to the HSC 
for genetic counseling. High-risk couples were informed about 
possible deleterious consequences on their offspring and about 
prenatal diagnosis and medical abortion of an affected fetus. 
They were informed that the couple took full personal responsi-
bility in proceeding with their marriage. Cases with presumed 
iron deficiency or with uncertain results were referred to Kocaeli 
University Hematology outpatient unit or the Genetics 
Department of Kocaeli University for further analysis (strip 
assays for mutation analysis of alpha- and beta-thalassemia). 
All demographic data of the couples (age, place of residence, 
place of birth and contact numbers) and detailed results of the 
assays were recorded in a computer prospectively.
During counseling, complete blood counts were repeated 
in fresh blood samples to avoid any difference in red blood cell 
indices due to storage. 
The frequency of hemoglobinopathy variants was calculated.
Bulgular: Toplam 88888 kişi taranmıştır. β-talasemi taşıyıcılığı sıklığı % 0,89, orak hücreli anemi taşıyıcılığı sıklığı % 0.05, 
homozigot hemoglobinopatili çocuğa sahip olma olasılığı olan çift oranı %0,01 bulunmuştur
Sonuç: Kocaeli ilinde β-talasemi ve orak hücreli anemi taşıyıcılığı sıklığı oldukça düşüktür. Sıklık kuzey ve doğu Anadoludaki 
oranları ve Kocaeli’ye bu bölgelerden olan göçü yansıtmaktadır. Bu hastalıklardaki kronik transfüzyon gereksinimi, 
şelazyonun yüksek maliyeti, organ hasarları, ağrılı krizler ve diğer krizler, kök hücre naklinin ancak dokusu uyumlu kardeşi 
olan sınırlı sayıda hastaya yapılabilmesi, evlilik öncesi tarama çalışmalarının Kocaeli gibi taşıyıcılık oranlarının düşük olduğu 
bölgelerde de gerekli olduğunu düşündürmektedir. (Turk J Hematol 2009; 26: 62-6)
Anahtar kelimeler: β,-talasemi taşıyıcılığı, evlilik öncesi tarama, orak hücreli anemi taşıyıcılığı
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In the last 3.5 years, 88,888 people were screened in the 
premarital screening program. The frequencies of β-thalassemia 
trait, sickle cell trait, HbD trait and HbC trait were 0.89%, 
0.05%, 0.09% and 0.009%, respectively. The frequency of 
high-risk couples was 0.01% (Table 1). Other variants are pre-
sented in Table 2.
There were borderline HbA2 levels in 9 samples and iso-
lated high HbF levels with normal hematologic values in 78 
samples. 
Discussion
In the present study, prevalence of β-thalassemia carriers 
was 0.89%, which is not very high. When compared to some 
screening studies from Turkey, prevalence of the thalassemia 
trait in Kocaeli is similar to that of Erzurum. Sickle cell carriage, 
which was 0.05%, was similar to that of Konya (Table 3) [3-9]. 
Çavdar O.A et al performed the first screening study in Turkey 
by measuring HbA2  levels in Ankara from 900 blood samples 
of Turkish Army members and Medical School and 100 cord 
blood samples collected from the City Maternity Hospital and 
reported an incidence of 1.66% for β-thalassemia trait [10].   
The highest β-thalassemia prevalence was in Antalya and 
Thrace (10%) and Muğla (4.8%). The frequency is lowest in 
eastern and northern Anatolia [11]. In a screening study from 
schools of Gaziantep, the prevalence of β-thalassemia trait 
was 1.84%, while it was 1% (n=995) in the Elbistan district of 
Kahramanmaraş and 3% in İzmir [12-14]. Kocaeli as a region 
of industry has migration from north, east and central Anatolia. 
The low prevalence may be a reflection of this heterogeneous 
population. National population statistics (data of Türkiye 
İstatistik Kurumu) showed that between 1985-1995, 83,262 
people migrated to Kocaeli, with a migration rate of 108.2 per 
thousand. This migration rate was even higher than in İstanbul, 
which was 107 per thousand during the same period. In 2000, 
the year following the Marmara earthquake, the increase in the 
population in Kocaeli was only 211 people because there was 
also migration from Kocaeli. 
The prevalence of sickle cell trait was also low in the pres-
ent study. Sickle cell trait is the second most common hemo-
globinopathy in Turkey, with the highest frequency in the 
Çukurova region (Adana, Hatay and Mersin, 10%) [15]. 
In the present study, HbD, HbE Saskatoon, HbO Arab and 
HbC seemed to be the most prevalent variants after 
β-thalassemia and sickle cell hemoglobinopathy. In a screening 
study from Kahramanmaraş, the prevalences of HbD and HbO 
Arab carriers were 0.28% and 0.013%, respectively [16]. 
Heterozygous states of Hb C, D, and E occur globally with suf-
ficient frequency to be considered a polymorphism [17]. HbE is 
the most common structural hemoglobin variant globally; it is 
innocuous in heterozygous and homozygous state but HbEβ 
thalassemia is a serious condition [17]. Detection of some vari-
ants depends on the equipment. Although the detected vari-
ants are presented in Table 3, we believe that it is not possible 
to give a true prevalence. Many of the variants were detected 
with an analyzer we used in 2008. A genetic analysis to confirm 
these variants may be necessary. 
In premarital screening studies it is very important to inform 
couples who are going to marry and each of them are carriers 
have the risk to have homozygote child with thalassemia. 
In a previous study, premarital screening was performed on 
2113 couples and both partners were found to be carriers in 
35 families. Prenatal diagnosis was performed in 10 pregnan-
cies of these families [18] instead of 19.  Following studies were 
done after this first premarital screening study [4,7,9,18,19]. 
In the screening study, there were 9 people with borderline 
HbA2 and 78 people with elevated HbF. Silent carriers of 
β-thalassemia and the possibility of other thalassemic types 
such as α-thalassemia carriers represent a significant dilemma 
in defining disorders. The presence of a single β-thalassemia 
allele is usually associated with hypochromic microcytic red 
cells and increase in HbA2 levels, but some alleles may show 
a silent phenotype (type 1) with normal or borderline hemato-
logical levels and HbA2 due to β-thalassemia genotype or the 
interaction of this genotype with other molecular defects (α-, 
δ-thalassemia). People with borderline HbA2 (3.1-3.9) must 
undergo molecular genetic studies, particularly if the partner is 
a carrier of β-thalassemia, to avoid missing at-risk couples [20]. 
A typical hematological feature of the β-thalassemia trait is 
MCV <79 fl, MCH <27 pg, and HbA2 >3.4. In β-thalassemia 
trait, the level of HbF is elevated in 50% of cases, usually to 1 
to 3% and rarely to 5% [17]. If there is a combination of β- and 
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Table 1. Screened population and frequency of hemoglobinopathies during premarital screening
Year   Screened  β-thalassemia  β-thalassemia  Hb S carrier  Borderline  High HbF  High-risk   
     population  carrier  intermedia    HbA2 values   >2%**  couples
2005*    9,495    67  0  6  6  17  2
2006   25,019  199  0  6  2  20  3
2007   27,310  262  1  21  0  21  4
2008   27,064  265  0  17  1  20  3
total   88,888  793  1  50  9  78  12
*6 months of 2005.
** Isolated high HbF with normal hematologic values and normal HbA2δ-thalassemia, the clinical picture may resemble the 
β-thalassemia trait. HbF level is higher, in the range of 5-20%, 
and the A2 level is normal or slightly reduced. MCV and MCH 
may be higher [17]. In α-thalassemia trait, Hb electrophoresis 
is normal. There may be minimal hematologic changes and 
there is no reliable way of making the diagnosis except by DNA 
analysis.
As is known people homozygotes for (δβ)° thalassemia   
have 100% HbF and their blood shows mild thalassemic 
changes with reduced MCV and MCH values, very similar to 
the  β-thalassemia trait. Heterozygotes have approximately 
20-30% HbF with slightly reduced HbA2 values and com-
pletely normal blood pictures [17]. 
During screening, some abnormal hemoglobins could not 
be defined. This feature was reported in molecular genetic 
analysis of β-thalassemia by Tadmouri et al. [21]. They sug-
gested that samples can have a relatively high number of 
unidentified mutations, especially samples of individuals origi-
nating from southern and eastern Anatolia. They explained the 
possible presence of rare and novel mutations in these isolated 
areas where consanguineous marriages are practiced exten-
sively. Our cases were not partners of hemoglobinopathy car-
riers but they were informed and a molecular genetic study 
was recommended. 
The expected number of the infants born with β-thalassemia 
major annually is calculated to be 150-200 in Turkey. 
Approximately 800 pregnant women should seek prenatal 
diagnosis each year [22]. Screening for hemoglobinopathies is 
important even in regions with lower prevalence. Consanguineous 
marriages may increase high-risk couples. A cost-benefit 
analysis of prevention programs showed that the total cost of 
the program in preventing birth of a single child with thalas-
semia major was equal to or less than the cost of treating a 
patient for one year [23]. 
Follow-up of high-risk couples and acquisition of informa-
tion about cancellation of the marriage, pregnancies and health 
of offspring were generally impossible due to unreliable phone 
numbers/addresses of the couples. A meaningful study evalu-
ating the efficiency of premarital screening in Hatay showed 
that only 17.5% of pregnant high-risk couples underwent pre-
natal diagnosis despite genetic counseling [6]. These results 
show that education in the hemoglobinopathy prevention pro-
gram is still inefficient. Especially couples with a low educa-
tional background can not fully comprehend the subject during 
premarital screening and genetic counseling. In a screening 
center in the Gaza Strip, a video about a thalassemia family is 
presented to carriers and explained by one of the staff, who is 
a thalassemia patient [24]. This method will be more effective 
in increasing the carrier’s familiarity with the subject. Employing 
thalassemic patients in these centers also seems to be a good 
idea. Despite religious restriction in the community regarding 
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Table 2. Some hemoglobin variants detected during screening
     2005 2006  2007*  2008  Total
Hb D   12  41  37  33  87
Hb E Saskatoon  2  1  2  10  15
Hb O Arab  -  -  -  13  13
Hb C   2  4  5  1  8
B Wayne  -  -  -  5  5
Hb G-Coushatta  -  -  -  2  2
Hb G-Copenhagen  -  -  -  2  2
HbS Florida  -  -  -  2  2
Hb Tayne  -  -  -  1  1
Hb Riyadh  -  -  -  1  1
Hb Strumica  -  -  -  1  1
Hb Le-Lamentin   -  -  -  1  1
Hb Hasharon  -  -  -  1  1
Hb Loves Park  -  -  -  1  1
Hb Rhode Island   -  -  -  1  1
Hb J-Anatoliae   -  -  -  1  1
Hb J-Meerut  -  -  -  1  1
Hb Anamosa  -  -  -  1  1
Hb Beograd  -  -  -  1  1
* There were 6 undefined hemoglobinopathies
Table 3. Premarital screening studies from Turkey
Author/year  Province  Number of  Prevalence of   Prevalence of
       screened people  β–thalassemia carriers  sickle cell carriers  
Kılınç M et al.* 1999  İçel 6746  3.1%  6.4%
Keskin A et al. 2000  Denizli  19804  2.6%  0.11%
Bolaman Z et al. 2001  Denizli  14200  2.2%  ND
Gali E et al. 2001  Hatay  10207  3%  8%
Güler E et al. 2007  Konya  72918  2%  0.05%
Acemoğlu H et al. 2007  Erzurum  1610  0.68%  0
Güler E et al. 2008  Kahramanmaraş 11040  2.3%  0.54%
Sarper N et al. 2009  Kocaeli  88888  0.89%  0.05%
*Also includes screenings in schools and community screeningabortion, free prenatal diagnosis must also be available. 
Relevant educational programs in schools and in the media are 
essential complements of any control program [25]. 
Hemoglobinopathy screening programs in addition to edu-
cation programs should be improved and expanded through-
out the country. The high morbidity of hemoglobinopathies, 
chronic transfusion requirements, high cost of chelating, organ 
damage, painful crisis and other crisis, and availability of stem 
cell transplantation for only a limited number of patients with 
compatible sibling donors justify premarital screening studies 
even in regions with lower prevalence such as Kocaeli. 
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